AstraZeneca and Daiichi Sankyo detailed Phase 3 data showing Enhertu (trastuzumab deruxtecan) can improve outcomes when moved into earlier breast‑cancer settings, with trial leaders framing the findings as opening the door to higher cure rates. Presentations at ESMO reported improved event‑free and pathological response metrics in patients treated before surgery or in early systemic disease. Company analysts and conference commentators framed the results as potential label expansion that could add tens of thousands of patients to Enhertu’s addressable market. Investigators emphasized durability signals and the need to monitor for known ADC toxicities, including interstitial lung disease, as the drug migrates into curative‑intent cohorts. The data underscore the broader industry trend of bringing next‑generation targeted cytotoxics into earlier lines of therapy and will prompt regulatory filings and payer discussions about cost, sequencing and long‑term safety monitoring.